Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life

Gregory Pugnet; Christian Pagnoux; Benjamin Terrier; Elodie Perrodeau; Xavier Puéchal; Alexandre Karras; Chahéra Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quemeneur; Claire Blanchard-Delaunay; Pascal Godmer; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maïzé Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon; Loïc Guillevin

Journal articles

Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life

Gregory Pugnet ^{1, 2, 3} Christian Pagnoux ³ Benjamin Terrier ^{4, 3} Elodie Perrodeau ^{5, 6} Xavier Puéchal ³ Alexandre Karras ⁷ Chahéra Khouatra Olivier Aumaître ⁸ Pascal Cohen ³ François Maurier ⁹ Olivier Decaux ¹⁰ Jacques Ninet ¹¹ Pierre Gobert Thomas Quemeneur ¹² Claire Blanchard-Delaunay Pascal Godmer Pierre-Louis Carron Pierre-Yves Hatron ¹³ Nicolas Limal Mohamed Hamidou ¹⁴ Maïzé Ducret Eric Daugas ¹⁵ Thomas Papo ¹⁶ Bernard Bonnotte ¹⁷ Alfred Mahr ¹⁸ Philippe Ravaud ⁶ Luc Mouthon ³ Loïc Guillevin ³

1 Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse

2 Service de Néphrologie et Immunopathologie Clinique, Centre Hospitalier Universitaire de Toulouse

3 Service de médecine interne et centre de référence des maladies rares [CHU Cochin]

4 DHU - I2B - Departement Hospitalo- Universitaire - Inflammation, Immunopathologie, Biothérapie [Paris]

5 CRESS - U1153 - Equipe 5 : METHODS - Méthodes de l’évaluation thérapeutique des maladies chroniques

UPD5 - Université Paris Descartes - Paris 5, CRESS (U1153 / UMR_A_1125 / UMR_S_1153) - Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité

6 CRESS (U1153 / UMR_A_1125 / UMR_S_1153) - Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité

7 Service de Néphrologie et Hémodialyse [CHU HEGP]

8 Service de médecine interne, hôpital Gabriel-Montpied

9 Service de médecine interne

10 IGDR - Institut de Génétique et Développement de Rennes

11 Service de Médecine Interne

12 VALENCIENNES - Med Int - Département de Médecine Interne

13 Service de médecine interne [Lille]

14 Service de médecine interne [Nantes]

15 Immunopathologie rénale, récepteurs et inflammation

16 Hôpital Bichat - Claude Bernard

17 LNC - Lipides - Nutrition - Cancer (U866)

18 Hôpital Saint-Louis

Abstract : OBJECTIVES: To investigate the effects on health-related quality of life (HRQOL) and functional capability of rituximab vs azathioprine for ANCA-associated vasculitis (AAV) maintenance therapy. METHODS: In a 24-month phase III randomised-controlled trial, 115 patients over time received rituximab or azathioprine for AAV maintenance therapy. Mean changes of 36-item Short-form Health Survey (SF-36) and Health Assessment Questionnaire (HAQ) scores from baseline were analysed. RESULTS: Mean improvements of HAQ scores, from baseline to month 24 were significantly better for the rituximab (0.16 points lower) than the azathioprine group (p=0.038). As demonstrated by SF-36, study patients' baseline HRQOL was significantly impaired compared with age- and sex-matched US norms. At month 24, mean changes from baseline of SF-36 physical component score tended to be better for the rituximab group (+3.95 points, p=0.067) whereas mean changes from baseline of the SF-36 mental component score were significantly better for the azathioprine group (+4.23 points, p=0.041). CONCLUSIONS: Azathioprine-treated patients' for AAV maintenance therapy showed a decline in physical abilities when compared to RTX at M24 in the MAINRITSAN trial. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov/, NCT00748644

Document type :

Journal articles

Domain :

Life Sciences [q-bio]

Complete list of metadata

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01302407
Contributor : Laurent Jonchère <>
Submitted on : Thursday, April 14, 2016 - 11:21:41 AM
Last modification on : Wednesday, May 26, 2021 - 8:08:03 PM

Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life

Identifiers

Collections

Citation

Export

Metrics

501

Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life

Identifiers

Collections

Citation

Export

Share

Metrics

501